Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7082-7087

  Metz, Richard ^a   DuHadaway, James B ^a   Kamasani, Uma ^a   Laury Kleintop, Lisa ^a   Muller, Alexander J ^a,b   Prendergast, George C ^a,b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN BETA; DEXTRO 1 METHYLTRYPTOPHAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 2; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INITIATION FACTOR 2ALPHA; N METHYLTRYPTOPHAN; TRANSCRIPTION FACTOR; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CATABOLISM; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEIN-BETA; DENDRITIC CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LEUKEMIA INHIBITORY FACTOR; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 34547643025     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1872     Document Type: Article

References (20)

1. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
2. Puccetti P. On watching the watchers: IDO and type I/II IFN. Eur JImmunol 2007;37:876-9.
3. Cady SG, Sono M. 1-Methyl-DL-tryptophan, β-(3-benzofuranyl) -DL-alanine (the oxygen analog of tryptophan), and β-[3- benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291:326-33.
4. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3.
5. Mellor AL, Sivakumar J, Chandler PKS, Molina H, Mao D, Munn DH. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001;2:64-8.
6. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
7. Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Can cer 2002;101:151-5.
8. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
9. Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
10. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40.
11. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
12. 2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 2006;103:2311-6.
13. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22:633-42.
14. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Diff 2002;9:1069-77.
15. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-61.
16. Belladonna ML, Grohmann U, Guidetti P, et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. JImm unol 2006;177:130-7.
17. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991;67:569-79.
18. + subset. J Immunol 2000;165:1357-63.
19. + dendritic cells. Eur J Immunol 2007;37:1064-71.
20. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396:203-13.